These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32470492)

  • 81. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
    van Raalte DH; Bjornstad P; Persson F; Powell DR; de Cassia Castro R; Wang PS; Liu M; Heerspink HJL; Cherney D
    Diabetes Care; 2019 Oct; 42(10):1921-1929. PubMed ID: 31371432
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial.
    Rasmussen DGK; Hansen MK; Blair J; Jatkoe TA; Neal B; Karsdal MA; Genovese F
    Cardiovasc Diabetol; 2022 Nov; 21(1):261. PubMed ID: 36443792
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study.
    Januzzi JL; Butler J; Sattar N; Xu J; Shaw W; Rosenthal N; Pfeifer M; Mahaffey KW; Neal B; Hansen MK
    Diabetes Care; 2021 Jan; 44(1):210-216. PubMed ID: 33158949
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program.
    Weir MR; Slee A; Sun T; Balis D; Oh R; de Zeeuw D; Perkovic V
    Clin Kidney J; 2021 May; 14(5):1396-1402. PubMed ID: 34221371
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The importance of targeting multiple risk markers in patients with type 2 diabetes: A post-hoc study from the CANVAS programme.
    Tye S; Oshima M; Arnott C; Neuen BL; Fletcher RA; Neal B; Heerspink HJL
    Diabetes Obes Metab; 2023 Jun; 25(6):1638-1645. PubMed ID: 36782264
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Canagliflozin: increased risk of toe amputations? Do not use this drug in diabetes.
    Prescrire Int; 2016 Oct; 25(175):243. PubMed ID: 30645831
    [No Abstract]   [Full Text] [Related]  

  • 88. Are SGLT2 Inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?
    Zoungas S; Polkinghorne KR
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1694-1695. PubMed ID: 33214159
    [No Abstract]   [Full Text] [Related]  

  • 89. Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program.
    Nunes JC; Yu J; Arnott C; Jardine MJ; Perkovic V; Mahaffey KW
    Diabetes Obes Metab; 2022 Dec; 24(12):2459-2464. PubMed ID: 35938182
    [No Abstract]   [Full Text] [Related]  

  • 90. Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy.
    Durkin M; Blais J
    Diabetes Ther; 2021 Feb; 12(2):499-508. PubMed ID: 33340064
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report.
    Phadke G; Kaushal A; Tolan DR; Hahn K; Jensen T; Bjornstad P; Roncal-Jimenez C; Hernando AA; Lanaspa MA; Alexander MP; Kukla A; Johnson RJ
    Am J Kidney Dis; 2020 Jul; 76(1):144-147. PubMed ID: 32387022
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Urate-Lowering Therapy Ameliorates Kidney Function in Type 2 Diabetes Patients With Hyperuricemia.
    Ueno N
    J Clin Med Res; 2017 Dec; 9(12):1007-1012. PubMed ID: 29163735
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The efficacy and safety of canagliflozin in the treatment of patients with early diabetic nephropathy.
    Zhang FP; Jiang X
    J Physiol Pharmacol; 2022 Feb; 73(1):. PubMed ID: 35639038
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Predictive Factors of Renal Function Decline in Patients with Type 2 Diabetes Treated with Canagliflozin in the Real-Wecan Study.
    Gorgojo-Martinez JJ; Brito-Sanfiel M; Antón-Bravo T; Galdón Sanz-Pastor A; Wong-Cruz J; Gargallo Fernández MA
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233490
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
    Tsoukas MA; Woo V; Tobe SW; Slee A; Rapattoni W; Ang FG; Seufert J; Neuen BL; Arnott C; Mahaffey KW; Wheeler DC
    Diabetes Obes Metab; 2023 Jul; 25(7):2038-2042. PubMed ID: 36942888
    [No Abstract]   [Full Text] [Related]  

  • 96. Mediators of the effects of canagliflozin on N-terminal pro-brain natriuretic peptide concentration: An exploratory mediation analysis of the randomized CANDLE trial.
    Tanaka A; Imai T; Suzuki M; Hiramitsu S; Takahashi N; Kadokami T; Kiyosue A; Nishino M; Sakata Y; Node K;
    Diabetes Obes Metab; 2022 May; 24(5):962-965. PubMed ID: 35112456
    [No Abstract]   [Full Text] [Related]  

  • 97. Canagliflozin Reduces the Risk of Kidney Failure in Patients with Type 2 Diabetes Mellitus and Nephropathy: The CREDENCE Randomized Trial.
    Halalau A; Fuller W; Wheeler S
    J Gen Intern Med; 2021 Feb; ():. PubMed ID: 33547569
    [No Abstract]   [Full Text] [Related]  

  • 98. Canagliflozin and myocardial oxidative stress: SGLT1 inhibition takes centre stage.
    Schiattarella GG; Bode D
    Eur Heart J; 2021 Dec; 42(48):4961-4963. PubMed ID: 34370850
    [No Abstract]   [Full Text] [Related]  

  • 99. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A
    Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL
    J Am Soc Nephrol; 2020 Dec; 31(12):2925-2936. PubMed ID: 32998938
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Dapagliflozin in Patients with Chronic Kidney Disease.
    Heerspink HJL; Stefánsson BV; Correa-Rotter R; Chertow GM; Greene T; Hou FF; Mann JFE; McMurray JJV; Lindberg M; Rossing P; Sjöström CD; Toto RD; Langkilde AM; Wheeler DC;
    N Engl J Med; 2020 Oct; 383(15):1436-1446. PubMed ID: 32970396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.